Androgen receptor biology in prostate cancer

Drug Management of Prostate Cancer

Volumn , Issue , 2010, Pages 61-70

  Gelmann, Edward P ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Androgen; Androgen receptor; Beta catenin; Coactivator; Mutation; p160; Prostate cancer

Indexed keywords

EID: 84855835884     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-60327-829-4_5     Document Type: Chapter

References (134)

1. Tomlins SA, Rhodes DR, Perner S et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310(5748):644-648.
2. Tomlins SA, Laxman B, Varambally S et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008; 10(2):177-188.
3. Huggins C, Stevens RE, Hodges CL. Studies on prostatic cancer II. The effect of castration on clinical patients with carcinoma of the prostate. Arch Surg 1941; 43:209.
4. Huggins C, Hodges C V. Studies on prostatic cancer; effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1:293-297.
5. Sadi MV, Walsh PC, Barrack ER. Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer 1991; 67:3057-3064.
6. Trachtenberg J, Walsh PC. Correlation of prostatic nuclear androgen receptor content with duration of response and survival following hormonal therapy in advanced prostatic cancer. J Urol 1982; 127(3):466-471.
7. Gonor SE, Lakey WH, McBlain WA. Relationship between concentrations of extractable and matrix-bound nuclear androgen receptor and clinical response to endocrine therapy for prostatic adenocarcinoma. J Urol 1984; 131(6):1196-1201.
8. Benson RC, Jr., Gorman PA, O'Brien PC, Holicky EL, Veneziale CM. Relationship between androgen receptor binding activity in human prostate cancer and clinical response to endocrine therapy. Cancer 1987; 59(9): 1599-1606.
9. Rennie PS, Bruchovsky N, Goldenberg SL. Relationship of androgen receptors to the growth and regression of the prostate. Am J Clin Oncol 1988; 11:S13.
10. Castellanos JM, Galan A, Calvo MA, Schwartz S. Predicting response of prostatic carcinoma to endocrine therapy. Lancet 1982; 1(8269):448.
11. Chen CD, Welsbie DS, Tran C et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10(1):33-39.
12. Roy AK, Lavrovsky Y, Song CS et al. Regulation of andro-gen action. Vitam Horm 1999; 55:309-352.
13. Gelmann EP. Androgen receptor mutations in prostate cancer. Cancer Treat Res 1996; 87:285-302.
14. Chang C, Saltzman A, Yeh S et al. Androgen receptor: an overview. Crit Rev Eukaryot Gene Expr 1995; 5(2): 97-125.
15. Lindzey J, Kumar MV, Grossman M, Young C, Tindall DJ. Molecular mechanisms of androgen action. Vitam Horm 1994; 49:383-432.
16. Quigley CA, De Bellis A, Marschke KB, el Awady MK, Wilson EM, French FS. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev 1995; 16(3):271-321.
17. Buchanan G, Greenberg NM, Scher HI, Harris JM, Marshall VR, Tilley WD. Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 2001; 7(5): 1273-1281.
18. Janne OA, Moilanen AM, Poukka H et al. Androgen-receptor-interacting nuclear proteins. Biochem Soc Trans 2000; 28(4):401-405.
19. Taplin ME, Ho SM. Clinical review 134: the endocrinology of prostate cancer. J Clin Endocrinol Metab 2001; 86(8): 3467-3477.
20. Bentel JM, Tilley WD. Androgen receptors in prostate cancer. J Endocrinol 1996; 151(1):1-11.
21. Lubahn DB, Joseph DR, Sullivan PM, Willard HF, French FS, Wilson EM. Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 1988; 240(4850):327-330.
22. Brown CJ, Goss SJ, Lubahn DB et al. Androgen receptor locus on the human X chromosome: regional localization to Xq11-12 and description of a DNA polymorphism. Am J Hum Genet 1989; 44(2):264-269.
23. Wisniewski AB, Migeon CJ, Meyer-Bahlburg HF et al. Complete androgen insensitivity syndrome: long-term medical, surgical, and psychosexual outcome. J Clin Endocrinol Metab 2000; 85(8):2664-2669.
24. Lubahn DB, Brown TR, Simental JA et al. Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identifcation of a point mutation in a family with complete androgen insensitivity. Proc Natl Acad Sci USA 1989; 86(23):9534-9538.
25. Kuiper GG, Faber PW, van Rooij HC et al. Structural organization of the human androgen receptor gene. J Mol Endocrinol 1989; 2(3):R1-R4.
26. Faber PW, van Rooij HC, Schipper HJ, Brinkmann AO, Trapman J. Two different, overlapping pathways of transcription initiation are active on the TATA-less human androgen receptor promoter. The role of Sp1. J Biol Chem 1993; 268(13):9296-9301.
27. Tilley WD, Marcelli M, Wilson JD, McPhaul MJ. Characterization and expression of a cDNA encoding the human androgen receptor. Proc Natl Acad Sci USA 1989; 86:327-331.
28. Spencer JA, Watson JM, Lubahn DB et al. The androgen receptor gene is located on a highly conserved region of the X chromosomes of marsupial and monotreme as well as eutherian mammals. J Hered 1991; 82(2):134-139.
29. Choong CS, Kemppainen JA, Wilson EM. Evolution of the primate androgen receptor: a structural basis for disease. J Mol Evol 1998; 47(3):334-342.
30. Matias PM, Donner P, Coelho R et al. Structural evidence for ligand specifcity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem 2000; 275(34):26164-26171.
31. Sack JS, Kish KF, Wang C et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci USA 2001; 98(9): 4904-4909.
32. Shiau AK, Barstad D, Loria PM et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998; 95(7):927-937.
33. Brzozowski AM, Pike AC, Dauter Z et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389(6652):753-758.
34. Tanenbaum DM, Wang Y, Williams SP, Sigler PB. Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc Natl Acad Sci USA 1998; 95(11):5998-6003.
35. Nolte RT, Wisely GB, Westin S et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 1998; 395(6698):137-143.
36. Wong CI, Zhou ZX, Sar M, Wilson EM. Steroid requirement for androgen receptor dimerization and DNA binding. Modulation by intramolecular interactions between the NH2-terminal and steroid-binding domains. J Biol Chem 1993; 268(25):19004-19012.
37. Langley E, Zhou ZX, Wilson EM. Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer. J Biol Chem 1995; 270(50):29983-29990.
38. Liao M, Zhou Z, Wilson EM. Redox-dependent DNA binding of the purifed androgen receptor: evidence for disulfde-linked androgen receptor dimers. Biochemistry 1999; 38(30):9718-9727.
39. Simental JA, Sar M, Lane MV, French FS, Wilson EM. Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem 1991; 266(1):510-518.
40. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991; 352(6330):77-79.
41. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004; 25(2):276-308.
42. Hsiao PW, Lin DL, Nakao R, Chang C. The linkage of Kennedy's neuron disease to ARA24, the frst identifed androgen receptor polyglutamine region-associated coacti-vator. J Biol Chem 1999; 274(29):20229-20234.
43. Irvine RA, Ma H, Yu MC, Ross RK, Stallcup MR, Coetzee GA. Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. Hum Mol Genet 2000; 9(2):267-274.
44. Sartor O, Zheng Q, Eastham JA. Androgen receptor gene CAG repeat length varies in a race-specifc fashion in men without prostate cancer. Urology 1999; 53(2):378-380.
45. Andersson P, Varenhorst E, Soderkvist P. Androgen receptor and vitamin D receptor gene polymorphisms and prostate cancer risk. Eur J Cancer 2006; 42(16):2833-2837.
46. Silva NB, Koff WJ, Biolchi V et al. Polymorphic CAG and GGC repeat lengths in the androgen receptor gene and prostate cancer risk: analysis of a Brazilian population. Cancer Invest 2008; 26(1):74-80.
47. Mittal RD, Mishra D, Mandhani AK. Role of an androgen receptor gene polymorphism in development of hormone refractory prostate cancer in Indian population. Asian Pac J Cancer Prev 2007; 8(2):275-278.
48. Patino-Garcia B, Arroyo C, Rangel-Villalobos H et al. Association between polymorphisms of the androgen and vitamin D receptor genes with prostate cancer risk in a Mexican population. Rev Invest Clin 2007; 59(1):25-31.
49. Krishnaswamy V, Kumarasamy T, Venkatesan V, Shroff S, Jayanth VR, Paul SF. South Indian men with reduced CAG repeat length in the androgen receptor gene have an increased risk of prostate cancer. J Hum Genet 2006; 51(3): 254-257.
50. Giwercman C, Giwercman A, Pedersen HS et al. Polymorphisms in genes regulating androgen activity among prostate cancer low-risk Inuit men and high-risk Scandinavians. Int J Androl 2008; 31(1):25-30.
51. Buchanan G, Yang M, Cheong A et al. Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum Mol Genet 2004; 13(16): 1677-1692.
52. Robins DM, Albertelli MA, O'Mahony OA. Androgen receptor variants and prostate cancer in humanized AR mice. J Steroid Biochem Mol Biol 2008; 108(3-5): 230-236.
53. Visakorpi T, Hyytinen E, Koivisto P et al. In vivo amplif-cation of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9(4):401-406.
54. Koivisto P, Visakorpi T, Kallioniemi OP. Androgen receptor gene amplifcation: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer. Scand J Clin Lab Invest Suppl 1996; 226:57-63.
55. Miyoshi Y, Uemura H, Fujinami K et al. Fluorescence in situ hybridization evaluation of c-myc and androgen receptor gene amplifcation and chromosomal anomalies in prostate cancer in Japanese patients. Prostate 2000; 43(3):225-232.
56. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplifcation and overexpres-sion of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001; 61(9):3550-3555.
57. Palmberg C, Koivisto P, Hyytinen E et al. Androgen receptor gene amplifcation in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade. Eur Urol 1997; 31(2):216-219.
58. Taplin ME, Bubley GJ, Shuster TD et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995; 332(21):1393-1398.
59. Taplin ME, Bubley GJ, Ko YJ et al. Selection for androgen receptor mutations in prostate cancers treated with andro-gen antagonist. Cancer Res 1999; 59(11):2511-2515.
60. Tilley WD, Buchanan G, Hickey TE, Bentel JM. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996; 2(2):277-285.
61. Tan J, Sharief Y, Hamil KG et al. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 1997; 11(4): 450-459.
62. Marcelli M, Ittmann M, Mariani S et al. Androgen receptor mutations in prostate cancer. Cancer Res 2000; 60(4): 944-949.
63. Barrack ER. Androgen receptor mutations in prostate cancer. Mt Sinai J Med 1996; 63(5-6):403-412.
64. Culig Z, Hobisch A, Hittmair A et al. Androgen receptor gene mutations in prostate cancer. Implications for disease progression and therapy. Drugs Aging 1997; 10(1):50-58.
65. Wang C, Uchida T. [Androgen receptor gene mutations in prostate cancer]. Nippon Hinyokika Gakkai Zasshi 1997; 88(5):550-556.
66. Suzuki H, Sato N, Watabe Y, Masai M, Seino S, Shimazaki J. Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 1993; 46(6):759-765.
67. Newmark JR, Hardy DO, Tonb DC et al. Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 1992; 89(14):6319-6323.
68. Wallen MJ, Linja M, Kaartinen K, Schleutker J, Visakorpi T. Androgen receptor gene mutations in hormone-refractory prostate cancer. J Pathol 1999; 189(4):559-563.
69. Castagnaro M, Yandell DW, Dockhorn-Dworniczak B, Wolfe HJ, Poremba C. [Androgen receptor gene mutations and p53 gene analysis in advanced prostate cancer]. Verh Dtsch Ges Pathol 1993; 77:119-123.
70. Veldscholte J, Voorhorst-Ogink MM, Bolt-de Vries J, van Rooij HC, Trapman J, Mulder E. Unusual specifcity of the androgen receptor in the human prostate tumor cell line LNCaP: high affnity for progestagenic and estrogenic steroids. Biochim Biophys Acta 1990; 1052(1):187-194.
71. De BA, Quigley CA, Cariello NF et al. Single base mutations in the human androgen receptor gene causing complete androgen insensitivity: rapid detection by a modifed denaturing gradient gel electrophoresis technique. Mol Endocrinol 1992; 6(11):1909-1920.
72. Jakubiczka S, Werder EA, Wieacker P. Point mutation in the steroid-binding domain of the androgen receptor gene in a family with complete androgen insensitivity syndrome (CAIS). Hum Genet 1992; 90(3):311-312.
73. Ahmed SF, Cheng A, Dovey L et al. Phenotypic features, androgen receptor binding, and mutational analysis in 278 clinical cases reported as androgen insensitivity syndrome. J Clin Endocrinol Metab 2000; 85(2):658-665.
74. Van YH, Lin JL, Huang SF, Luo CC, Hwang CS, Lo FS. Novel point mutations in complete androgen insensi-tivity syndrome with incomplete mullerian regression: two Taiwanese patients. Eur J Pediatr 2003; 162(11): 781-784.
75. Bouvattier C, Carel JC, Lecointre C et al. Postnatal changes of T, LH, and FSH in 46, XY infants with mutations in the AR gene. J Clin Endocrinol Metab 2002; 87(1):29-32.
76. Takahashi H, Furusato M, Allsbrook WC, Jr. et al. Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men. Cancer Res 1995; 55(8):1621-1624.
77. Haapala K, Hyytinen ER, Roiha M et al. Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Lab Invest 2001; 81(12):1647-1651.
78. Gregory CW, Johnson RT, Jr., Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001; 61(7):2892-2898.
79. Chen G, Wang X, Zhang S et al. Androgen receptor mutants detected in recurrent prostate cancer exhibit diverse functional characteristics. Prostate 2005; 63(4):395-406.
80. Jagla M, Feve M, Kessler P et al. A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions. Endocrinology 2007; 148(9):4334-4343
81. Buchanan G, Yang M, Harris JM et al. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol Endocrinol 2001; 15(1):46-56.
82. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L. Nuclear receptor coactivators and corepres-sors. Mol Endocrinol 1996; 10(10):1167-1177.
83. Greenberg NM, DeMayo F, Finegold MJ et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995; 92(8):3439-3443.
84. Wang Q, Lu J, Yong EL. Ligand-and coactivator-mediated transactivation function (AF2) of the androgen receptor ligand-binding domain is inhibited by the cognate hinge region. J Biol Chem 2001; 276:7493-7499.
85. He B, Bowen NT, Minges JT, Wilson EM. Androgen-induced NH2-and COOH-terminal Interaction Inhibits p160 coactivator recruitment by activation function 2. J Biol Chem 2001; 276(45):42293-42301.
86. Gregory CW, Fei X, Ponguta LA et al. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 2004; 279(8): 7119-7130.
87. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 2004; 6(5):517-527.
88. Gregory CW, Whang YE, McCall W et al. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res 2005; 11(5): 1704-1712.
89. Liu Y, Majumder S, McCall W et al. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res 2005; 65(8): 3404-3409.
90. Mahajan NP, Liu Y, Majumder S et al. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci USA 2007; 104(20):8438-8443.
91. Ponguta LA, Gregory CW, French FS, Wilson EM. Site specifc androgen receptor serine phosphorylation linked to epidermal growth factor dependent growth of castration-recurrent prostate cancer. J Biol Chem 2008; 283(30): 20989-21001.
92. Sun M, Yang L, Feldman RI et al. Activation of phosphati-dylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. J Biol Chem 2003; 278(44):42992-43000.
93. Guo Z, Dai B, Jiang T et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 2006; 10(4):309-319.
94. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008; 68(13):5469-5477.
95. Mohler JL, Gregory CW, Ford OH, III et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10(2):440-448.
96. Stanbrough M, Bubley GJ, Ross K et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66(5):2815-2825.
97. Locke JA, Guns ES, Lubik AA et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008; 68(15):6407-6415.
98. Trachtenberg J, Halpern N, Pont A. Ketoconazole: a novel and rapid treatment for advanced prostatic cancer. J Urol 1983; 130(1):152-153.
99. Trachtenberg J, Pont A. Ketoconazole therapy for advanced prostate cancer. Lancet 1984; 2(8400):433-435.
100. Small EJ, Halabi S, Dawson NA et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004; 22(6): 1025-1033.
101. Attard G, Reid AH, Yap TA et al. Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone acetate, con-frms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26(28): 4563-4571.
102. O'Donnell A, Judson I, Dowsett M et al. Hormonal impact of the 17alpha-hydroxylase/C(17, 20)-lyase inhibitor abi-raterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004; 90(12):2317-2325.
103. Alen P, Claessens F, Verhoeven G, Rombauts W, Peeters B. The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. Mol Cell Biol 1999; 19(9):6085-6097.
104. Chmelar R, Buchanan G, Need EF, Tilley W, Greenberg NM. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer 2007; 120(4):719-733.
105. Gregory CW, He B, Johnson RT et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001; 61(11):4315-4319.
106. Agoulnik IU, Vaid A, Bingman WE, III et al. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 2005; 65(17):7959-7967.
107. Bevan CL, Hoare S, Claessens F, Heery DM, Parker MG. The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol Cell Biol 1999; 19(12):8383-8392.
108. Agoulnik IU, Vaid A, Nakka M et al. Androgens modulate expression of transcription intermediary factor 2, an andro-gen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res 2006; 66(21):10594-10602.
109. Zhou HJ, Yan J, Luo W et al. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res 2005; 65(17):7976-7983.
110. Miyamoto H, Yeh S, Wilding G, Chang C. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci USA 1998; 95(13):7379-7384.
111. Halkidou K, Gnanapragasam VJ, Mehta PB et al. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 2003; 22(16): 2466-2477.
112. Ngan ES, Hashimoto Y, Ma ZQ, Tsai MJ, Tsai SY. Overexpression of Cdc25B, an androgen receptor coactiva-tor, in prostate cancer. Oncogene 2003; 22(5):734-739.
113. Heemers HV, Sebo TJ, Debes JD et al. Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Res 2007; 67(7):3422-3430.
114. Taneja SS, Ha S, Swenson NK et al. ART-27, an androgen receptor coactivator regulated in prostate development and cancer. J Biol Chem 2004; 279(14):13944-13952.
115. Fujimoto N, Yeh S, Kang HY et al. Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. J Biol Chem 1999; 274(12):8316-8321.
116. Wang X, Yang Y, Guo X et al. Suppression of androgen receptor transactivation by Pyk2 via interaction and phos-phorylation of the ARA55 coregulator. J Biol Chem 2002; 277(18):15426-15431.
117. Voeller HJ, Truica CI, Gelmann EP. Beta-catenin mutations in human prostate cancer. Cancer Res 1998; 58(12): 2520-2523.
118. Chesire DR, Ewing CM, Sauvageot J, Bova GS, Isaacs WB. Detection and analysis of beta-catenin mutations in prostate cancer. Prostate 2000; 45(4):323-334.
119. Watanabe M, Kakiuchi H, Kato H et al. APC gene mutations in human prostate cancer. Jpn J Clin Oncol 1996; 26(2):77-81.
120. Gerstein AV, Almeida TA, Zhao G et al. APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer 2002; 34(1):9-16.
121. Henrique R, Ribeiro FR, Fonseca D et al. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res 2007; 13(20):6122-6129.
122. Mulholland DJ, Dedhar S, Wu H, Nelson CC. PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. Oncogene 2006; 25(3): 329-337.
123. Rubinfeld B, Albert I, Porfri E, Fiol C, Munemitsu S, Polakis P. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 1996; 272(5264):1023-1026.
124. Rios-Doria J, Kuefer R, Ethier SP, Day ML. Cleavage of beta-catenin by calpain in prostate and mammary tumor cells. Cancer Res 2004; 64(20):7237-7240.
125. Truica CI, Byers S, Gelmann EP. Beta-catenin affects androgen receptor transcriptional activity and ligand speci-fcity. Cancer Res 2000; 60(17):4709-4713.
126. Yang F, Li X, Sharma M et al. Linking beta-catenin to androgen-signaling pathway. J Biol Chem 2002; 277(13): 11336-11344.
127. Mulholland DJ, Cheng H, Reid K, Rennie PS, Nelson CC. The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli. J Biol Chem 2002; 277(20):17933-17943.
128. Pawlowski JE, Ertel JR, Allen MP et al. Liganded androgen receptor interaction with beta-catenin: nuclear co-localization and modulation of transcriptional activity in neuronal cells. J Biol Chem 2002; 277(23):20702-20710.
129. Song LN, Herrell R, Byers S, Shah S, Wilson EM, Gelmann EP. Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription. Mol Cell Biol 2003; 23(5):1674-1687.
130. Song LN, Gelmann EP. Interaction of {beta}-Catenin and TIF2/GRIP1 in transcriptional activation by the androgen receptor. J Biol Chem 2005; 280(45):37853-37867.
131. Liao G, Chen LY, Zhang A et al. Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J Biol Chem 2003; 278(7):5052-5061.
132. Song LN, Coghlan M, Gelmann EP. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Mol Endocrinol 2004; 18(1): 70-85.
133. Masiello D, Chen S Y, Xu Y et al. Recruitment of beta-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells. Mol Endocrinol 2004; 18(10):2388-2401.
134. Hodgson MC, Astapova I, Hollenberg AN, Balk SP. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. Cancer Res 2007; 67(17):8388-8395.